730 related articles for article (PubMed ID: 18220746)
1. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
4. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
6. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
Neckers L
Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
8. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
10. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
11. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
12. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
13. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
14. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
[TBL] [Abstract][Full Text] [Related]
16. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
17. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
18. 17 AAG for HSP90 inhibition in cancer--from bench to bedside.
Usmani SZ; Bona R; Li Z
Curr Mol Med; 2009 Jun; 9(5):654-64. PubMed ID: 19601813
[TBL] [Abstract][Full Text] [Related]
19. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
